for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cesca Therapeutics Inc

KOOL.OQ

Latest Trade

5.33USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.10

 - 

5.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.33
Open
--
Volume
--
3M AVG Volume
3.92
Today's High
--
Today's Low
--
52 Week High
5.56
52 Week Low
2.10
Shares Out (MIL)
2.42
Market Cap (MIL)
12.88
Forward P/E
-11.84
Dividend (Yield %)
--

Next Event

Q3 2019 Cesca Therapeutics Inc Earnings Release

Latest Developments

More

Cesca Therapeutics And Thermogenesis Announce Major Global Distribution Deal For The Company's X-Series Products

Cesca Therapeutics Announces Q2 Loss Per Share $0.47

Cesca Therapeutics Inc says On July 23, Entered Into And Closed Transaction Contemplated By Securities Purchase Agreement With Accredited Investor

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cesca Therapeutics Inc

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Industry

Scientific & Technical Instr.

Contact Info

2711 Citrus Rd

+1.916.8585100

http://www.cescatherapeutics.com/

Executive Leadership

Xiaochun Xu

Chairman of the Board, President, Chief Executive Officer

Jeffery Cauble

Principal Financial Officer, Principal Accounting Officer

Venkatesh Ponemone

Executive Director of India Operations, Director of Clinical and Scientific Affairs

Kimberly Ellner

Vice President of Manufacturing and Global Supply Chain

Russell M. Medford

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.712

2018

-3.600

2019(E)

-0.450
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.99
Price To Book (MRQ)
2.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
42.00
LT Debt To Equity (MRQ)
42.00
Return on Investment (TTM)
-95.25
Return on Equity (TTM)
-68.29

Latest News

BRIEF-Cesca Prices $5.5 Million Public Offering

* CESCA THERAPEUTICS INC - IS OFFERING UNITS AT A PRICE OF $0.60 PER UNIT.

BRIEF-Cesca Therapeutics Reports Q1 Loss Per Share $0.27

* CESCA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Cesca Therapeutics Says Offering Up To 3.2 Million Units

* CESCA THERAPEUTICS SAYS OFFERING UP TO 3.2 MILLION UNITS, EACH UNIT CONSISTING OF 1 SHARE OF COMMON STOCK, ONE COMMON WARRANT TO PURCHASE 1 SHARE OF STOCK Source text: (https://bit.ly/2I8M01T) Further company coverage:

BRIEF-Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility

* CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING

BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Announces Registered Direct Offering

* CESCA THERAPEUTICS INC - PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO 609,636 SHARES OF STOCK AT A PURCHASE PRICE OF $2.27 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing

* CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES

BRIEF-Cesca Therapeutics Files For Common Stock Offering Of Up To $15 Mln

* FILES FOR COMMON STOCK OFFERING OF UP TO $15 MILLION - SEC FILING Source text: (http://bit.ly/2E1uKu2) Further company coverage:

BRIEF-Cesca Therapeutics Announces Proposed Public Offering Of Common Stock

* CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics appoints Joe Balagot as senior vice president of corporate development

* Cesca Therapeutics appoints healthcare investment banking veteran Joe E. Balagot as senior vice president of corporate development Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics reports quarterly loss per share $0.24

* Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update

BRIEF-Cesca Therapeutics ‍receives Notice of Allowance for U.S. patent application covering a novel method of cell separation​

* Cesca Therapeutics Inc - receives Notice of Allowance for U.S. patent application covering a novel method of cell separation Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics announces distribution agreement with Boyalife WSN

* Cesca Therapeutics announces international distribution agreement with Boyalife WSN Ltd.

BRIEF-Cesca Therapeutics announces issuance of new cellular processing patent

* Cesca Therapeutics announces issuance of new cellular processing patent poised to revolutionize CAR-T cell manufacturing Source text for Eikon: Further company coverage:

BRIEF-Cesca Therapeutics says acquires cell processing systems of SynGen

* Cesca therapeutics acquires the cell processing systems of syngen under asset acquisition agreement

BRIEF-Cesca Therapeutics Q3 loss per share $0.21

* Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update

BRIEF-Cesca Therapeutics announces closing of $5 mln revolving line of credit

* Cesca Therapeutics announces closing of $5 million revolving line of credit

BRIEF-Cesca Therapeutics enters into a revolving credit agreement

* On March 6, 2017 Co entered into a revolving credit agreement with Boyalife Investment Fund II - SEC filing

BRIEF-Cesca Therapeutics appoints Vivian Liu chief operating officer

* Cesca Therapeutics Inc - Vivian Liu appointed as chief operating officer and elected Russell Medford to its board of directors Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up